No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin
Secondary prophylaxis using inhaled colistin (IC) was implemented to prevent recurrences of Pseudomonas aeruginosa or extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) pneumonia during the postoperative intensive care unit (ICU) stay after lung transplantation (LT). We evaluated the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Transplant International |
| Subjects: | |
| Online Access: | https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13545/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590556283273216 |
|---|---|
| author | Nathalie Grall Nathalie Grall Maksud Assadi Marina Esposito-Farese Brice Lortat-Jacob Sébastien Tanaka Sébastien Tanaka Enora Atchade Jonathan Messika Jonathan Messika Jonathan Messika Vincent Bunel Hervé Mal Hervé Mal Pierre Mordant Pierre Mordant Pierre Mordant Yves Castier Yves Castier Bastien Garnier Signara Gueye Marie Petitjean Erick Denamur Laurence Armand-Lefevre Laurence Armand-Lefevre Charles Burdet Philippe Montravers Philippe Montravers Alexy Tran-Dinh Alexy Tran-Dinh |
| author_facet | Nathalie Grall Nathalie Grall Maksud Assadi Marina Esposito-Farese Brice Lortat-Jacob Sébastien Tanaka Sébastien Tanaka Enora Atchade Jonathan Messika Jonathan Messika Jonathan Messika Vincent Bunel Hervé Mal Hervé Mal Pierre Mordant Pierre Mordant Pierre Mordant Yves Castier Yves Castier Bastien Garnier Signara Gueye Marie Petitjean Erick Denamur Laurence Armand-Lefevre Laurence Armand-Lefevre Charles Burdet Philippe Montravers Philippe Montravers Alexy Tran-Dinh Alexy Tran-Dinh |
| author_sort | Nathalie Grall |
| collection | DOAJ |
| description | Secondary prophylaxis using inhaled colistin (IC) was implemented to prevent recurrences of Pseudomonas aeruginosa or extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) pneumonia during the postoperative intensive care unit (ICU) stay after lung transplantation (LT). We evaluated the risk of emergence of colistin resistance in the respiratory tract during secondary IC prophylaxis. We conducted a prospective, single-centre, observational study of all adult patients who underwent LT between 1 July 2018 and 30 June 2019. IC was started and continued for at least 90 days for P. aeruginosa or ESBL-PE pneumonia. During the 90 days following LT, all respiratory samples were routinely tested for the presence of GNB of reduced susceptibility to colistin. Twenty-seven (38.6%) of the 70 included patients received IC. Among the 867 respiratory samples tested, IC did not promote the emergence of bacterial species with natural or acquired resistance to colistin (incidence-rate ratio of 0.21 [0.03–1.58], p = 0.13 and 1.68 [0.55–5.12], p = 0.37, respectively). Our study suggests no association between the use of IC and an increased risk of colistin resistance in the respiratory tract within 90 days of LT. |
| format | Article |
| id | doaj-art-a8a8d79294ed4282be1614f10b801b18 |
| institution | Kabale University |
| issn | 1432-2277 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Transplant International |
| spelling | doaj-art-a8a8d79294ed4282be1614f10b801b182025-01-23T12:00:32ZengFrontiers Media S.A.Transplant International1432-22772025-01-013710.3389/ti.2024.1354513545No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled ColistinNathalie Grall0Nathalie Grall1Maksud Assadi2Marina Esposito-Farese3Brice Lortat-Jacob4Sébastien Tanaka5Sébastien Tanaka6Enora Atchade7Jonathan Messika8Jonathan Messika9Jonathan Messika10Vincent Bunel11Hervé Mal12Hervé Mal13Pierre Mordant14Pierre Mordant15Pierre Mordant16Yves Castier17Yves Castier18Bastien Garnier19Signara Gueye20Marie Petitjean21Erick Denamur22Laurence Armand-Lefevre23Laurence Armand-Lefevre24Charles Burdet25Philippe Montravers26Philippe Montravers27Alexy Tran-Dinh28Alexy Tran-Dinh29Université Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Service de Bactériologie, Paris, FranceINSERM UMR 1137 IAME, Université Paris Cité, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat, Département d’Epidémiologie et Recherche Clinique, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, FranceRéunion Island University, INSERM U1188 Diabetes Atherothrombosis Réunion Indian OCean (DéTROI), CYROI Plateform, Saint-Denis de La Réunion, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Pneumologie B et Transplantation Pulmonaire, Paris, FranceINSERM UMR 1152 PHERE, Université Paris Cité, Paris, FranceParis Transplant Group, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Pneumologie B et Transplantation Pulmonaire, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Pneumologie B et Transplantation Pulmonaire, Paris, FranceINSERM UMR 1152 PHERE, Université Paris Cité, Paris, FranceINSERM UMR 1152 PHERE, Université Paris Cité, Paris, FranceParis Transplant Group, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Service de Chirurgie Vasculaire, Thoracique et Transplantation Pulmonaire, Paris, FranceINSERM UMR 1152 PHERE, Université Paris Cité, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Service de Chirurgie Vasculaire, Thoracique et Transplantation Pulmonaire, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Service de Bactériologie, Paris, FranceINSERM UMR 1137 IAME, Université Paris Cité, Paris, FranceINSERM UMR 1137 IAME, Université Paris Cité, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Service de Bactériologie, Paris, FranceINSERM UMR 1137 IAME, Université Paris Cité, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat, Département d’Epidémiologie et Recherche Clinique, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, FranceINSERM UMR 1152 PHERE, Université Paris Cité, Paris, FranceUniversité Paris Cité, AP-HP, Hôpital Bichat Claude Bernard, Département d’Anesthésie-Réanimation, Paris, France0INSERM UMR 1148 LVTS, Université Paris Cité, Paris, FranceSecondary prophylaxis using inhaled colistin (IC) was implemented to prevent recurrences of Pseudomonas aeruginosa or extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE) pneumonia during the postoperative intensive care unit (ICU) stay after lung transplantation (LT). We evaluated the risk of emergence of colistin resistance in the respiratory tract during secondary IC prophylaxis. We conducted a prospective, single-centre, observational study of all adult patients who underwent LT between 1 July 2018 and 30 June 2019. IC was started and continued for at least 90 days for P. aeruginosa or ESBL-PE pneumonia. During the 90 days following LT, all respiratory samples were routinely tested for the presence of GNB of reduced susceptibility to colistin. Twenty-seven (38.6%) of the 70 included patients received IC. Among the 867 respiratory samples tested, IC did not promote the emergence of bacterial species with natural or acquired resistance to colistin (incidence-rate ratio of 0.21 [0.03–1.58], p = 0.13 and 1.68 [0.55–5.12], p = 0.37, respectively). Our study suggests no association between the use of IC and an increased risk of colistin resistance in the respiratory tract within 90 days of LT.https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13545/fullcolistinresistancelung transplantationprophylaxispneumonia |
| spellingShingle | Nathalie Grall Nathalie Grall Maksud Assadi Marina Esposito-Farese Brice Lortat-Jacob Sébastien Tanaka Sébastien Tanaka Enora Atchade Jonathan Messika Jonathan Messika Jonathan Messika Vincent Bunel Hervé Mal Hervé Mal Pierre Mordant Pierre Mordant Pierre Mordant Yves Castier Yves Castier Bastien Garnier Signara Gueye Marie Petitjean Erick Denamur Laurence Armand-Lefevre Laurence Armand-Lefevre Charles Burdet Philippe Montravers Philippe Montravers Alexy Tran-Dinh Alexy Tran-Dinh No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin Transplant International colistin resistance lung transplantation prophylaxis pneumonia |
| title | No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin |
| title_full | No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin |
| title_fullStr | No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin |
| title_full_unstemmed | No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin |
| title_short | No Emergence of Colistin Resistance in the Respiratory Tract of Lung Transplant Patients Treated With Inhaled Colistin |
| title_sort | no emergence of colistin resistance in the respiratory tract of lung transplant patients treated with inhaled colistin |
| topic | colistin resistance lung transplantation prophylaxis pneumonia |
| url | https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13545/full |
| work_keys_str_mv | AT nathaliegrall noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT nathaliegrall noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT maksudassadi noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT marinaespositofarese noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT bricelortatjacob noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT sebastientanaka noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT sebastientanaka noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT enoraatchade noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT jonathanmessika noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT jonathanmessika noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT jonathanmessika noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT vincentbunel noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT hervemal noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT hervemal noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT pierremordant noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT pierremordant noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT pierremordant noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT yvescastier noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT yvescastier noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT bastiengarnier noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT signaragueye noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT mariepetitjean noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT erickdenamur noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT laurencearmandlefevre noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT laurencearmandlefevre noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT charlesburdet noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT philippemontravers noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT philippemontravers noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT alexytrandinh noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin AT alexytrandinh noemergenceofcolistinresistanceintherespiratorytractoflungtransplantpatientstreatedwithinhaledcolistin |